in this issue
Regions :: Western Europe :: U.K.
AstraZeneca acquires ADC technology firm Spirogen
7:55 AM MDT | October 16, 2013 | Deepti Ramesh
AstraZeneca (London) says that its biologics R&D arm, MedImmune (Gaithersburg, MD), has acquired Spirogen (London), a privately held biotech company focused on antibody-drug conjugate (ADC) technology for use in oncology. MedImmune has also entered into a collaboration agreement with ADC Therapeutics (Lausanne, Switzerland) to jointly develop two of ADC Therapeutics’ ADC programs in preclinical development, AstraZeneca says. MedImmune will also make an equity investment in ADC Therapeutics, which has an existing licensing agreement with Spirogen...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee